Compare Medpace Holdings Inc (MEDP) vs Occidental Petroleum Corporation (OXY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medpace Holdings Inc vs Occidental Petroleum Corporation — how do they compare? Medpace Holdings Inc trades at $611.57 (market cap $16.82B), while Occidental Petroleum Corporation trades at $60.12 (market cap $60.26B). The key difference: Occidental Petroleum Corporation is far larger — about 3.6× Medpace Holdings Inc's market cap, and Occidental Petroleum Corporation pays a 1.86% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Medpace Holdings Inc for 14 Days and Occidental Petroleum Corporation for 92 Days on average.
| MEDP | OXY | |
|---|---|---|
Market Cap | $16.82B | $60.26B |
Volume | 223,093 | 11,718,920 |
Sector | Health | Energy |
52-Week High | $630.19 | $66.24 |
52-Week Low | $393.42 | $38.92 |
Typical Hold Time | 14 Days | 92 Days |
Enterprise Value | $16.44B | $79.02B |
Dividend Yield | — | 1.86% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Medpace (MEDP) trades at $617.47, up 2.19% with strong quarterly earnings beats and robust profitability metrics. The stock shows neutral technical signals with key resistance at $620, while fundamentals reveal impressive ROE of 162.15% and consistent revenue growth to $2.8B projected for 2026. Recent CEO stock sales and mixed institutional activity create balanced sentiment ahead of Q3 earnings announcement on October 21, 2026.
MEDP presents growth potential with analyst consensus target of $620.44 and strong historical execution, though elevated valuations (P/E 35.41) and insider selling warrant caution. The stock's upside depends on continued earnings delivery amid competitive medical services landscape.
Occidental Petroleum (OXY) trades at $60.11, up 3.26% with strong technical momentum and bullish moving averages. The company demonstrates robust profitability with 30.32% net margin and 21.46% ROE, though revenue has declined from $36.6B in 2022 to $21.6B in 2025. Recent earnings beats and a $71.40 consensus price target suggest upside potential, supported by Goldman Sachs' October 2026 upgrade citing debt reduction and cash flow targets.
OXY presents a compelling value case with attractive valuation multiples (P/E 17.78, EV/EBITDA 5.56) and strong analyst support (52% buy ratings). Key risks include oil price volatility and declining revenue trends, while catalysts include Q3 2026 earnings on November 9 and continued execution on the $4B cash flow target. The stock's technical positioning near resistance at $61 requires monitoring for breakout confirmation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →About Occidental Petroleum Corporation
Occidental Petroleum is an independent exploration and production company with operations in the United States, Latin America, and the Middle East. At the end of 2021, the company reported net proved reserves of 3.5 billion barrels of oil equivalent. Net production averaged 1,174 thousand barrels of oil equivalent per day in 2021 at a ratio of 75% oil and natural gas liquids and 25% natural gas.
Read more on OXY →
